



ANTITUMOUR ACTIVITY OF THE 
ERK DIMERIZATION INHIBITOR 




MASTER IN MOLECULAR BIOLOGY AND BIOMEDICINE 
UNIVERSITY OF CANTABRIA 
2020/2021 
 





DIRECTOR: BERTA CASAR MARTÍNEZ 
CODIRECTOR: PIERO CRESPO BARAJA 
 







1. ABSTRACT .........................................................................................................................4 
2. BACKGROUND AND ACTUAL STATE OF THE TOPIC ...............................................5 
2.1 Lung adenocarcinoma ........................................................................................................5 
2.2The ERK1/2 signalling pathway ..........................................................................................6 
2.3 The RAS-ERK pathway in cancer ......................................................................................8 
2.4 RAS-ERK pathway alterations in lung adenocarcinoma ....................................................9 
2.5 Current status of MAPK pathway inhibitors in cancer therapy ........................................ 10 
2.6 Progress in Piero’s laboratory........................................................................................... 14 
3. OBJECTIVES .................................................................................................................... 15 
4. MATERIALS AND METHODS ....................................................................................... 16 
4.1 Cell culture ....................................................................................................................... 16 
4.2 Treatment with inhibitors ................................................................................................. 16 
4.3 Protein isolation ............................................................................................................... 16 
4.4 Protein concentration measurement .................................................................................. 16 
4.5 Immunoblotting ................................................................................................................ 16 
4.6 ERK1/2 dimers detection ................................................................................................. 17 
4.7 Measurement of proliferation and survival rates .............................................................. 18 
4.8 IC50 calculation ................................................................................................................. 18 
4.9 Preparation of cells for confocal fluorescence microscopy ............................................... 19 
4.10 Cell migration analysis ................................................................................................... 19 
4.11 Cell invasion analysis ..................................................................................................... 19 
4.12 Preparing tumour cells for grafting ................................................................................. 20 
4.13 Chicken embryo xenografting ........................................................................................ 20 
4.13 Harvesting tumours and chick embryo tissues ................................................................ 21 
4.14 Genomic DNA isolation ................................................................................................. 21 
4.15 RT-qPCR analysis .......................................................................................................... 22 
3 
 
5. RESULTS .......................................................................................................................... 23 
5.1 DEL-22379 inhibits ERK dimerization without affecting its phosphorylation in A549 cells
 ............................................................................................................................................... 23 
5.2 DEL-22379 IC50 calculation in A549 cells ....................................................................... 26 
5.3 DEL-22379 effectively diminishes cell survival in lung adenocarcinoma cells ................ 27 
5.4 A549 cells migration is reduced by the ERK dimerization inhibitor DEL-22379............. 28 
5.5 DEL-22379 reduces tumour growth in the chick embryo model ...................................... 30 
6. DISCUSSION .................................................................................................................... 31 
7. CONCLUSIONS ................................................................................................................ 34 





















Lung cancer is the leading cause of cancer-related mortality in both men and women worldwide. 
The most frequent type is lung adenocarcinoma, which accounts for 40% of all lung cancer cases. 
The RAS-RAF-MEK-ERK pathway (MAPK pathway) is known for being essential in cellular 
functions such as cell proliferation, differentiation, and apoptosis. Due to its important roles 
regulating cell functions, the MAPK pathway is commonly altered in many tumours, including 
lung adenocarcinomas. In the last years, numerous inhibitors of the cascade have been developed, 
and some of them have even progressed into the clinics. The most successful ones have been RAF 
and MEK inhibitors. However, patients treated with these drugs usually present relapses because 
of acquired resistance. For this reason, ERK has been recently considered as a potential target in 
cancer therapy, although ERK mutations rarely occur in tumours. In previous results from our 
laboratory, researchers have demonstrated that the prevention of ERK dimerization is a viable 
strategy to supress oncogenesis and tumour growth.  Using a novel ERK dimerization screening 
method, Crespo et al. discovered a compound capable of effectively inhibiting ERK dimerization, 
which they called DEL-22379. This drug presented several antineoplastic properties in melanoma 
and colorectal cancer cells, such as generation of apoptotic response, a decrease of the tumour 
mass and lower metastatic spread. To further investigate the inhibitor’s potential, the purpose of 
this study is to analyse the antitumour effects of DEL-22379 in lung adenocarcinoma, in both cell 















2. BACKGROUND AND ACTUAL STATE OF THE TOPIC 
2.1 Lung adenocarcinoma 
Lung cancer is the most common cause of cancer-related deaths in men and women in the world 
(Barta et al., 2019). Its appearance has a strong association with cigarette smoking, but it is also 
linked to other risk factors, like ionizing radiation, environmental toxins, metals (arsenic 
chromium and nickel), history of pulmonary fibrosis, human immunodeficiency virus infection 
and alcohol consumption (Duma et al., 2019). 
Most lung cancers are in an advanced stage when diagnosed, and consequently, the prognosis is 
very poor. More than 80% of patients with advanced lung cancer are dead by 5 years (Myers & 
Wallen, 2021), and the longevity of the patients has not increased over the past 3 decades. 
Therefore, screening and prevention are on the spotlight. 
Symptoms and physical signs are dependent on the stage of lung cancer.  The earliest stages are 
often asymptomatic, with nodules found incidentally on radiographic images testing for other 
disease processes. Later stage lung cancer usually exhibit symptoms such as a cough, hemoptysis, 
chest pain, dyspnea or unintentional weight loss (Duma et al., 2019).  
Adenocarcinoma, a type of non-small cell lung 
cancer (NSCLC), accounts for approximately 40% 
of lung cancers (Barta et al., 2019), replacing the 
squamous cell lung cancer as the most prevalent 
non-small cell lung cancer in the last two decades. 
In patients, adenocarcinomas often stain positively 
with antibodies to markers of the alveolar type II 
cells, the surfactant-producing epithelial cells in 
the alveolar space, or the bronchiolar epithelial 
club (Clara) cells, the secretory cells lining the 
airways (Rowbotham & Kim, 2014). These cell 
types are thought to be responsible for tumour 
origin. Lung adenocarcinoma is classified into four subtypes: adenocarcinoma in situ, minimally 
invasive adenocarcinoma, invasive adenocarcinoma, and lepidic predominant adenocarcinoma 
(Lambe et al., 2020). 
Over the last 40 years, there has been a marked increase in lung adenocarcinoma in women, and 
this has been linked to smoking. An immense majority of patients will have a smoking history 
and may have other associated factors such as chronic obstructive pulmonary disease or a family 
history of lung cancer  (Myers & Wallen, 2021).  
Figure 1. Minimally invasive 
adenocarcinoma histopathology. (H&E, 
20×). (Lambe et al., 2020). 
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Local metastasis may involve spread directly to the pleura, diaphragm, pericardium, or bronchi 
with advanced disease spreading to the mediastinum, great vessels, trachea, esophagus, vertebral 
column, or adjacent lobe. Distant metastasis includes extension to a contralateral lobe, pleural 
nodules, malignant pleural or pericardial effusion, or any distant site such as the brain, bones, or 
liver (Myers & Wallen, 2021).  
2.2The ERK1/2 signalling pathway 
The ERK1/2 pathway (sometimes referred as the MAPK pathway) is one of most studied MAPK 
(mitogen-activated protein kinases) cascades (Degirmenci et al., 2020; Guo et al., 2020; Kidger 
et al., 2018; Liu et al., 2018; McCubrey et al., 2007). This pathway is well defined due to its 
relevance in essential cellular functions, such as cell proliferation, growth, differentiation, cell 
cycle regulation and apoptosis.   
 
Figure 2. Structure of the MAPK pathway, representing the main components of the cascade 
and their interactions. (Liu et al., 2018). 
The RAS-RAF-MEK1/2-ERK1/2 signalling pathway is activated by a large variety of 
extracellular molecules, like growth factors, cytokines, hormones, and neuropeptides. This 
molecules function as stimuli when they bind to their receptor in the cell extracellular membrane, 
mainly tyrosine kinase receptors (RTKs), initiating the cascade. After the receptors are activated, 
they dimerize and autophosphorilate themselves. This allows the activation of the growth factor 
receptor-bound protein 2 (Grb2), which forms a complex with son of sevenless 1 (SOS1), a 
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guanine nucleotide exchange factor. SOS interchange GDP for GTP in the RAS molecule, making 
it active and recruiting it into the plasma membrane, functioning as a binary on-off switch of the 
pathway. 
RAS is a GTPase involved in numerous signalling routes, such as the ERK1/2 pathway. RAS 
superfamily includes over 150 small G-proteins, including K-RAS, H-RAS, N-RAS and others. 
When RAS is bound to GTP, it goes through a conformational change and is able to activate its 
downstream effector of the ERK1/2 pathway: RAF. 
RAF is a protein with serine/threonine protein kinase activity when it is bound to RAS in the inner 
layer of the plasma membrane, where they can change their phosphorylation state, dimerize, and 
interact with scaffold proteins. In mammals, RAF kinase comprises three isoforms with different 
tissue distribution and level of kinase activity: A-RAF, B-RAF and C-RAF (or RAF-1). When 
RAF is activated, it can phosphorylate the next kinase of the route, MEK.  
There are two MEK subtypes, MEK1 and MEK2. MEK is a dual specificity kinase that activates 
ERK by phosphorylating both of its Tyrosine and Threonine regulatory sites. ERK needs to be 
phosphorylated by MEK in the activation loop, which contains a characteristic TxY (threonine-
x-tyrosine) motif or TEY motif. ERK is the last kinase of the pathway and, as its upstream 
activator MEK, has two isoforms: ERK1 and ERK2. They are serine/threonine protein kinases, 
which can activate a wide range of cytoplasmatic and nuclear substrates, like transcription factors, 
phosphatases, and cytoskeletal proteins. The signal also promotes ERK dimerization, which is 
necessary for the activation of certain cytoplasmatic substrates. These substrates participate in the 
control cellular metabolism, mitochondrial fission, and cell survival. On the other hand, ERK 
function in the nucleus is mostly performed as a monomer. In the nucleus, ERK can activate 
transcription factors such as CREB, c-Myc and NF-kB. 
Although the RAS-ERK pathway is frequently described as linear and unidirectional, there are 
several interactions within the pathway and between other signalling networks that do not 
correspond with this description. One of the most relevant is the homeostatic control of the 
cascade by ERK using feedback loops. This regulation has rapid short-term effects, like ERK 
promoting the inhibition of upstream kinases like MEK, RAF and RTKs by phosphorylating 
certain residues. It can also produce a long-term feedback effect by stimulating the de novo 
expression of proteins like DUSPs, a dual-specificity phosphatase that inhibits the pathway by 
dephosphorylating ERK. 
In addition, the pathway is modulated by multiple regulatory proteins. Scaffold proteins are the 
most abundant of this group. They are characterized for been capable of binding at least two 
members of the cascade, forming a functionally stable complex. Beside their assembly 
capabilities, scaffold proteins can act as allosteric stimulators to optimize signal flux. Therefore, 
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these proteins can regulate the duration, amplitude, and intensity of the signal, as well as the 
spatial specificity (Casar & Crespo, 2016). 
To add more complexity to this pathway, RAS kinase can activate both MAPK and 
PI3K/AKT/mTOR pathway. Moreover, the dynamic interaction between RAS/ERK and  
RAS/PI3K cascades, by both positive and negative feedback loops, ensures the bidirectional 
communication with other pathways (Braicu et al., 2019). 
2.3 The RAS-ERK pathway in cancer 
The RAS-ERK signalling pathway is not only involved in physiological cellular processes, but 
the association of point mutations across the members within the cascade with tumour formation 
and poor prognosis has been described in numerous studies (Table 1).  
Table 1. Frequency of mutations in the main components of the MAPK pathway across 
different tumours. Adapted from Guo et al., 2020. 
 
RAS is mutated in approximately one-third of all cancers, with high prevalence in pancreas (90%), 
colon (50%), thyroid (50%), lung (30%) cancers and melanoma (25%) (Fernández-Medarde & 
Santos, 2011). RAS mutations mostly occur in K-RAS (85%), followed by N-RAS (12%) and H-
RAS (3%). Generally, mutated RAS proteins are constitutively bound to GTP. This leads to the 
continuous activation and phosphorylation of downstream effectors, with high levels of p-MEK 
and p-ERK. 
RAF was not considered a relevant cancer driver gene until the discovery of the B-RAF(V600E) 
mutation in 2002. This mutation represents more than the 90% of all RAF mutation events in 
cancer cells genomes, C-RAF and A-RAF mutations are much less common (Degirmenci et al., 
Tumour type K-RAS N-RAS H-RAS B-RAF MEK ERK
Melanoma 15-29% 20% - 90% 3-8% 67-90%
NSCLC 35% - - 4% - -
Colorectal 40% - - 5-20% 3% -
High-grade serous ovarian cancer 0-12% - - - - -
Low-grade serous ovarian cancer 27-36% - - 33-50% - -
Thyroid carcinoma 9-27% 9-27% 9-27% 10-70% - -
Papillary thyroid cancer 20% - - - - -
Anaplastic/follicular thyroid cancer - 15% - - - -
Hairy cell - - - 79-100% - -
Pancreatic ductal adenocarcinoma 70% - - - - -
Acute myleoid leukaemia 10% - - - - -
Bladder urotherial carcinoma - - 20% - - -
Renal cell carcnoma - - 2% - - -
Breast cancer 5% - - 1% 7-9% -
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2020). The mutations can cause different effects, like simulating phosphorylated state, disrupting 
the auto-inhibitory conformation, or activating the wild-type RAF counterparts.  
In contrast to RAS and RAF mutations, MEK mutations are considerably less frequent in cancer 
cells, but can act as cancer drivers. The mutations can interrupt the auto-inhibitory state or 
enhance MEK homodimerization (Degirmenci et al., 2020).  
Finally, ERK mutations rarely occur in cancers. ERK2E322k mutation has been detected in 
significant cases of cervical, head and neck squamous cell carcinomas. The mutated protein 
exhibits higher levels of activity due to defects in DUSP binding site, remaining in a 
phosphorylated state (Kidger et al., 2018). 
All these mutations ultimately lead to the persistent and increased activation of the RAS-ERK 
pathway, which is closely related to the occurrence and development of tumours. This activation 
can promote cellular functions typical of cancer cells. For example, it can stimulate proliferation 
and inhibit apoptosis by influencing the activity of cell cycle regulatory proteins and apoptosis-
related proteins in cancer cells (Maemura et al., 2009).  RAS-ERK signalling pathway activation 
can also lead to increased tumour invasion and metastasis capabilities by favouring the 
degradation of the extracellular matrix, cell migration and angiogenesis (Guo et al., 2020). Due 
to the importance of the pathway in tumours, the efforts made to understand the working 
mechanisms of the cascade and to target its components in cancer cells have grown in the last 
years. 
2.4 RAS-ERK pathway alterations in lung adenocarcinoma 
About 20-30% of lung adenocarcinomas present a mutation in the RAS gene. In fact, 
adenocarcinomas cases are the NSCLCs with higher frequency of K-RAS mutations than other 
subtypes (Boch et al., 2013). These mutations have been correlated with clinical and pathological 
characteristics of the patient, being more common in females and smokers. Furthermore, there are 
numerous evidences supporting that oncogenic K-RAS signalling, through the RAS-ERK 
pathway, can drive histological progression of adenomas to malignant carcinomas. (Cicchini 
et al., 2017). Other less prevalent RAS mutations, like in N-RAS, can be useful to foresee clinical 
and therapeutic features of the tumours.  
Mutations of the B-RAF proto-oncogene are common in melanomas but can also occur less 
frequently in other cancer types, like lung adenocarcinoma.  B-RAF is mutated in approximately 
4% of all NSCLCs (Guo et al., 2020).  
The epithelial growth factor receptor (EGFR) is a glycoprotein present in plasma membrane that 
can be stimulated by ligand such as EGF, TFGα or neuregilins to activate the MAPK pathway 
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and stimulate cellular proliferation (Bethune et al., 2010). When the ligand binds to EGFR, it 
dimerizes and phosphorylates itself, initiating the signalling cascade. Deregulation of EGFR has 
been observed in 40-89% of NSCLCs. Interestingly, it has been reported that the mutations that 
cause gain of function of both proto-oncogenes K-RAS and EGFR are mutually exclusive in lung 
adenocarcinomas, a phenomenon that can be explained by synthetic toxicity, which induces cell 
death (Unni et al., 2018). 
2.5 Current status of MAPK pathway inhibitors in cancer therapy 
Since the RAS-ERK pathway presents a wide variety of alterations in cancer genomes, it has 
attracted the interest of cancer researchers. Every protein of the cascade represents a potential 
druggable target to inhibit to stop signal propagation. In the last years, an enormous effort has 
been made by biomedical scientist to discover new compounds able of inhibiting the components 
of the MAPK pathway, in order to prevent tumour growth and propagation. 
The development RAS inhibitors has supposed a significant challenge, mostly due to the high 
GTP affinity of the mutants, which prevents GTP hydrolysis, and the lack of a binding pocket for 
small molecule inhibitor binding (Cox et al., 2014).  For these reasons, and for a long period of 
time, RAS protein was believed to be undruggable. Nonetheless, recent novel approaches have 
been developed to overcome these problems. For example, one of the strategies consist in 
targeting proteins that regulate RAS-GTP interaction, like SOS, which is a regulator of GDP/GTP 
exchange of RAS. Another promising alternative seems to be the inhibition of the functionally 
relevant post-translational modifications, like prenylation. In the case of lung adenocarcinomas, 
it has been reported that small molecule compounds (SML-8-73-1 and SML-10-70-1) can inhibit 
K-RAS G12C mutant (Lim et al., 2014). This mutation is present in almost half of RAS-driven 
lung adenocarcinomas. Despite the efforts made, the aforementioned approaches are limited to 
laboratory models, and the development of effective molecules showing clinical effectiveness is 
still far from the present. 
RAF, as the first kinase of the cascade, has been considered a valuable target against cancer. One 
of the first discovered molecules capable to inhibit RAF was Sorafenib, an orally available 
compound. It was originally described as a C-RAF isoform inhibitor, and later identified as a 
multikinase inhibitor. Sorafenib can inhibit angiogenesis and tumour growth, and has preclinical 
and clinical activity against certain types of cancers (for example, ovarian, breast and pancreatic 
cancer) (Fucile et al., 2015). Other first-generation RAF inhibitors include Vemurafenib, 
Dabrafenib and Encorafenib.  NSCLC patients harbouring the B-RAF V600E mutation have 
shown a good response to dabrafenib (Anguera & Majem, 2018). More recently, it has been 
observed that genetic ablation of C-RAF in K-RAS driven tumours induced significant rates of 
tumour regression in lung adenocarcinoma, suggesting that the inhibition of the activity or 
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expression of C-RAF might be a suitable therapeutic option (Drosten & Barbacid, 2020). Despite 
of the initial achievements of these drugs, tumours quickly develop resistance, leading to tumour 
progression and relapses (Degirmenci et al., 2020). Cancer cells can acquire resistance through 
two different mechanisms. First, they can increase the expression of the RAS protein, which leads 
to what is known as “paradoxical activation” of the RAS-ERK pathway. Secondly, the generation 
of a splicing variant of B-RAF(V600E) can enhance its dimerization and activity. Curiously, 
resistant cancer cells become drug-dependent, and dray withdrawal inhibits their growth and 
proliferation. To overcome the appearance of resistant tumours, a second generation of RAF 
inhibitors was developed. 
Because of their low mutation frequency in human cancers, MEK1/2 kinases were not considered 
acceptable targets against tumours. However, the emergence of resistance to RAF inhibitors, the 
interest in this kinase has grown among researchers. The first reported MEK1/2 inhibitor was 
PD098059, which can inhibit the dephosphorylated state of MEK1. U0126 and its high inhibition 
specificity towards MEK were discovered some years later, but its poor pharmacological 
properties relegated this drug as a research tool (Frémin & Meloche, 2010). PD0325901, an 
allosteric inhibitor that stabilizes the inactive conformation of MEK1/2, was one of the first 
inhibitors to reach clinical trials (Kohler et al., 2018).  The use of MEK inhibitors in combination 
with RAF inhibitors was found to be quite effective, especially in metastatic melanoma. 
Moreover, a significant number of studies have reported preclinical evidence of the effectiveness 
of MEK targeting therapies in NSCLC using inhibitors like Selumetinib and Trametinib (Abdel-
Rahman, 2016). However, like their RAF counterparts, MEK inhibitors rapidly generate drug 
resistance in treated cancer cells, both for monotherapy and combination therapy (Liu et al., 
2018). There are several mechanisms that allow cancer cells to respond against MEK targeted 
therapy, like the overactivation of upstream intermediaries of the pathway, MEK mutations, 
activation of parallel signalling pathways, transcription factors regulation, etc. In addition, due to 
their high ligand affinity, many MEK inhibitors also affect and non-cancerous cells in a 
considerable proportion, resulting in high toxicity and clinical limitations. 
EGFR inhibitors have also been used in cancer therapy. These molecules bind to EGFR, blocking 
the binding of alternative ligands, preventing the initiation of the signalling pathway (Pradhan 
et al., 2019). Approval of tyrosine kinase inhibitors such as Erlotinib, Gefitinib, and Lapatinib for 
the treatment of non-small cell lung cancer led to tremendous development of novel EGFR 
inhibitors in the last decade.  In fact, there are numerous preclinical studies showing the 
synergistic effects of EGFRi and MEKi combination therapy against NSCLC (Abdel-Rahman, 
2016), significantly reducing the generation of MEKi or EGFRi resistant tumours. However, 
almost all lung cancer cases experience disease recurrence after one to two years, mostly due to 
EGFR mutations that generate acquired resistance (Nagano et al., 2018). 
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Despite the initial successes of these kinase inhibitors, the apparently unavoidable drug resistance 
has emerged as the main problem when targeting the MAPK pathway in cancer. This resistance 
usually appears as a consequence of the activation of upstream elements of the cascade through 
various mechanisms.  Hence, targeting the most downstream kinase of the pathway was 
considered as viable alternative. Although ERK gene is rarely mutated in cancer cells, 
therapeutical inhibition of this kinase has several advantages. 
First, every alteration of the RAS-ERK pathway in cancer cells ultimately leads to the 
overactivation of ERK, which then is able to stimulate a wide variety of substrates. ERK1/2 
receives the information from MEK, which previously acquired it from RAF, and the passes it on 
to multiple targets. Thus, ERK1/2 can be seen as the bottleneck of the pathway. Therefore, when 
we consider the structure of the cascade, the inhibition of the last effector of the cascade seems 
the most optimal approach.  
Secondly, ERK inhibition can overcome the drug resistance originated by upstream kinases 
inhibitors. As it has been explained before, the acquired resistance to EGFR, RAF and MEK 
inhibitors implies the reactivation of the MAPK pathway by a series of mechanisms previously 
mentioned. It has been reported that selective ERK inhibitors can reverse this resistance (Liu 
et al., 2018). Moreover, it is believed that these inhibitors are less prone to generate drug 
resistance. 
As described before, the MAPK pathway presents negative ERK-dependent feedback loops that 
regulate the pathway. This results in the inhibition of RAF, MEK and RTK activity. However, 
when cells are treated with inhibitors that target these upstream kinases, they lose the regulation 
caused by the feedback loops, which leads to their subsequent activation and the reinstallation of 
the signal (Kidger et al., 2018).  This rebound is considerably stronger in cells carrying RAS 
mutations. If ERK is inhibited, the ERK-dependent feedback loops are also supressed. 
For all these advantages, a significant amount of small molecule inhibitors of ERK1/2 have been 
discovered and studied recently. Some have even progressed into clinical trials. There are many 
different types of ERK inhibitors.  
Reversible ATP-competitive ERK1/2 inhibitors attach to the active or inactive conformation of 
the ATP-binding pocket. Many of these drugs, including BVD-523 (Chin et al., 2020), also known 
as Ulixertinib, GDC-0994 and SCH772984 (Kidger et al., 2018), are now in clinical trials. Both 
are ATP-competitive inhibitors that suppress cell proliferation in cell lines with B-RAF or K-RAS 
mutations.  SCH772984 has been demonstrated to efficiently suppress both ERK1/2 catalytic 
activity and its phosphorylation by MEK1/2. The effectiveness of BVD-523 was also assessed in 
Vemurafenib-resistant patient-derived xenografts. It is also in phase I/II clinical studies for solid 
tumours and melanoma that resist RAF and MEK inhibitors.  
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Another type of inhibitors is the covalent ERK1/2 inhibitors. They bind to their target protein 
forming a covalent interaction that can be reversible or irreversible (Kidger et al., 2018). Because 
the covalent interaction results in either a very slow off-rate for the inhibitor or a permanently 
inhibited target protein, de novo synthesis of the target is required to re-establish activity, this 
method of inhibition is proposed to facilitate prolonged inhibition of the target protein and with 
high potency. Examples of these drugs include Afatinib, Neratinib, Ibrutinib and Osimertinib. 
Nonetheless, because of their intrinsic reactivity, covalent inhibitors may have off-target effects 
by interacting with cysteines and other reactive residues across the proteome. This makes it 
difficult for them to achieve success in clinical trials. 
A newer approach consists in the development of allosteric ERK1/2 inhibitors, which attach at 
locations other than the catalytic cleft and prevent ERK1/2 from interacting with its binding 
partners (Yap et al., 2011). The first small molecule allosteric ERKi was discovered in more than 
15 years ago, using computational design (Hancock et al., 2005). This type of inhibition allows 
the molecules to supress ERK phosphorylation, prevent dimerization, or selectively block the 
attachment to its substrates.  
In clinical studies, selective ERK inhibitors have been used to treat a great range of malignancies, 
the most prevalent of which are advanced solid tumours with MAPK pathway abnormalities. 
Melanoma, pancreatic adenocarcinoma, and non-small cell lung cancer were the most prevalent 
solid tumour malignancies treated in these clinical trials (Chin et al., 2020). There are several 
studies that support the therapeutic potential of ERK inhibitors in lung cancer. ERK inhibitors 
were used in Gefitinib (an EGFR inhibitor used to treat NSCLC patients) resistant cancer cell, 
successfully reverting this resistance (Qi et al., 2018). This was also verified for another EGFRi, 
Osimertinib (Li et al., 2020). A different ERKi, LY3214996, has shown promising results in 
experiments using patient-derived xenograft models of RAS-mutant lung cancer (Köhler et al., 
2021). 
Unfortunately, as observed with other MAPK pathway inhibitors, treatment with ERK inhibitors 
can also cause resistance in the clinic. Mutations in ERK1/2, ERK2 amplification and 
overexpression, and EGFR increased expression levels have all been identified as mechanisms of 
acquired resistance in resistant cell lines (Jaiswal et al., 2018). Moreover, ERK inhibitor resistant 
lung cancer cell lines have been generated in the laboratory. For example, Iezzi et al. created a 
SCH772984 resistant NSCLC cell line (Iezzi et al., 2018). 
To avoid resistance, combining ERK1/2 inhibitors with other kinase inhibitors seems a promising 
therapeutical approach, as in the case of RAFi. In B-RAF (V600E) melanoma, B-RAFi and ERKi 
combination is likely to be more effective and well tolerated than B-RAFi alone, as is the case 
with B-RAFi and MEKi combination (Kidger et al., 2018). In fact, the combination of MEK and 
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ERK inhibitors has been tested in lung adenocarcinoma A549 cells, where the mixed treatment 
of Cobimetinib (MEKi) and GDC-0994 (ERKi) significantly diminished tumoral activity in vivo, 
reducing the tumour growth in a synergic way (Merchant et al., 2017). Although in this particular 
experiment the doses where well tolerated by the animals used, for most of the cases the difficulty 
resides in balancing inhibitor synergy in the tumour cell with the increased toxicity caused by 
action in non-tumour tissue. 
2.6 Progress in Piero’s laboratory 
In previous studies in Piero’s laboratory, they discovered that ERK1/2 dimers and scaffolds are 
essential for optimum activation of cytoplasmic substrates. In fact, inhibiting ERK1/2 
dimerization can stop tumour cell proliferation in vitro, and oncogenesis and tumour development 
in vivo (Casar et al., 2008). This research established ERK1/2 dimerization as a possible target in 
tumours and opened new pathways for developing new ERK inhibitors. 
As a result, Herrero and colleagues devised a native gel 
electrophoresis method for screening of ERK1/2 
dimerization inhibitors (Herrero et al., 2015). DEL-22379 
(Figure 3), a 3-arylidene-2-oxindole derivative, was 
identified as a small molecule capable of inhibiting ERK1/2 
dimerization while having no effect on ERK1/2 
phosphorylation or catalytic activity in the tested cell lines. 
The DEL-22379 binding site on ERK2 is located in a cleft 
near the dimerization interface, adjacent to important 
dimerization residues such as His 176. This prevents the 
interaction between two ERK molecules.   
In this same study, it was demonstrated that DEL-22379 inhibited the phosphorylation of ERK1/2 
cytoplasmic substrates as well as the proliferation of RAS-ERK pathway oncogene-expressing 
tumour cell lines and xenografts. In xenografts from melanoma and colorectal cancer cell lines 
containing mutant B-RAF and RAS, DEL-22379 causes a significant apoptotic response, as well 
as a reduction in primary tumour mass and metastatic spread. 
Moreover, the inhibition of tumour growth by DEL-22379 was not affected by classical RAS-
ERK pathway inhibitor resistance mechanisms. DEL-22379 had the same antiproliferative effect 
in A375 melanoma cells which overexpressed a mutated N-RAS, as opposed to the failure of B-
RAF inhibitor PLX-4032.  Similar results were found in another experiment with HT29 colorectal 
cancer cells overexpressing B-RAF (V600E), where MEK inhibitor PD-0325901 treatment was 
unsuccessful and cells remained sensitive to DEL-22379.  
Figure 3. Structure of DEL-22379. 




To further investigate DEL-22379 capabilities of inhibiting ERK dimerization, we inspected the 
effects of this drug in lung adenocarcinoma cells, both in vitro and in vivo conditions*. 
To achieve this goal, A549 human lung adenocarcinoma cells were used, which are known to 
have a K-RAS mutation, while the EGFR is wild type. These cells have been used by other 
researchers as a model to study K-RAS driven lung tumours.  
Our initial hypothesis was that DEL-22379 can inhibit ERK dimerization in A549 cells. If this 
premise turned out to be true, similar effects in the molecular dynamics of the pathway and in the 
neoplastic capabilities, previously observed in experiments carried by Herrero et al., were 
expected to appear in A549 cells. This could define DEL-22379 as a potential therapeutic agent 
in lung adenocarcinoma. Thus, the next objectives arose to give a response to these questions: 
• Characterize the biochemical effects of DEL-22379 in A549 cells. ERK dimerization was 
examined, as well as the phosphorylation state of ERK. The activation or inactivation of 
different ERK substrates and other components of the pathway was also investigated. 
• Compare the survival, migratory and invasive capabilities of DEL-22379-treated and 
non-treated A549 cells in vitro.  
• Analyse the consequences of DEL-22349 treatment in A549 tumours in vivo, using the 
chick embryo animal model. 
To determine the efficacy of DEL-22379 as an inhibitor in these cancer cells, two other inhibitors 








*Because cells react to drugs differently in cell culture and in animal models, a distinction is made 
along this work. Experiments performed in cell cultures are considered in vitro conditions, while 




4. MATERIALS AND METHODS 
4.1 Cell culture 
A549 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin on a regular basis. When plates 
were confluent, they were washed with phosphate buffered saline (PBS) and detached using the 
appropriated volume of Trypsin/EDTA. Cells were kept in an incubator at 37 ° C, with 5% CO2 
and 98%relative humidity.  
4.2 Treatment with inhibitors 
To analyse the effects of each drug in lung cancer cells, A549 cells were previously starved for 
24 hours using serum-free DMEM. Then, they were incubated with the drug, which were 
dissolved in dimethyl sulfoxide (DMSO), for one hour. EGF (Epidermal Growth Factor, SIGMA) 
has been used to stimulate cells at 50 ng/mL final concentration for 5 minutes. 
4.3 Protein isolation 
To get a total protein extract from cell cultures, the plates were placed on ice and washed with 
PBS 1X to remove any residues. Then, 200-250μL of lysis buffer was added to each culture plate. 
The buffer contained 20mM HEPES pH 7.5, 10mM EGTA, 40mM β-glycerolphosphate, 1% of 
not ionic detergent NP40, 2.5mM MgCl2, 2mM orthovanadate, 1mM DTT (dithiothreitol) and 
proteases inhibitor (10μg/mL aprotinin and 10μg/mL leupeptin). Lysates were collected and 
centrifugated at 13000 rpm during 10 minutes at 4ºC. Supernatants containing proteins were 
separated from the pellet after centrifugation.  
4.4 Protein concentration measurement 
The colorimetric technique of Bradford with the DCTM (Detergent Compatible) Protein Assay 
kit from Bio-Rad was used to measure and determine protein concentration. Subsequently, to 5μL 
of total protein extract, 25μL of a 50:1 mixture of Protein Assay Reagent A and Protein Assay 
Reagent S were added. Then, 200L of Protein Assay Reagent B were combined with the mixture. 
After that, the solution was incubated for 10 minutes at 37°C. 
4.5 Immunoblotting 
Samples were mix with 4X Laemmli buffer (100mM Tris pH 6.8, 4% SDS, 20% glycerol, 20mM 
DTT and 0.005% bromophenol blue) in a 1:4 ratio (Laemmli:sample). Then, they were heated at 
during 95ºC 5 minutes. The mix was placed in the well of a polyacrylamide gel, which was 
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composed of a stacking part (composed of 4% acrylamide, 125 mM Tris-HCl pH 6.8, 0.4% 
sodium dodecyl sulfate (SDS), 0.1% Ammonium Persulfate (APS) and 0.1% Tetramethyl 
ethylenediamine (TEMED) in H2O) and a resolving part (the acrylamide percentage range was 
from 8% to 12% depending on the molecular weight of the protein, 375 mM Tris-HCl pH 8.8, 
0.4% SDS, 0.1% APS and 0.1% TEMED in H2O). Proteins were separated by size by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE). The vertical electrophoresis separation took 
around one hour at 120V in a Mini-protean Bio-Rad equipment with running buffer (25 mM 
Trizma base, 192 mM Glycine, 0,1% SDS). The proteins were then transferred to nitrocellulose 
membranes in transfer solution (25 mM Trizma base and 192 mM Glycine) at 400 mA constant 
amperage under refrigerating conditions. The membranes were incubated with blocking solution 
(4% bovine serum albumin or BSA). Then, two ten minutes washes were performed in TBS-T at 
room temperature and shaking. After blocking, the membranes were incubated with the primary 
antibody (diluted in TBS-T 4%BSA) for 1-2 hours or overnight. Another two washes were 
performed before secondary antibody incubation (TBS-T 4% milk). The secondary antibodies 
used were conjugated with peroxidase enzyme for enhanced chemiluminescence detection (ECL). 
For this the membrane was previously washed and treated with solution 1 (1 M Tris HCl pH 8.5, 
90 mM Coumaric Acid, 250 mM Luminol) and solution 2 (1 M Tris HCl pH 8.5, 30% Hydrogen 
Peroxide). 
Table 2. Primary antibodies used in this work. 
 
4.6 ERK1/2 dimers detection 
To detect dimerization of ERK, electrophoresis of the total cell lysate under native conditions was 
carried. This was achieved mixing the lysate with a specific loading buffer (0.126 M Tris HCl pH 
Antibody Specificity Dilution Reference 
Anti-ERK2 Mouse monoclonal 1:1000 sc-1647 
Anti-p-ERK Mouse monoclonal 1:4000 sc-7383 
Anti-ERK1/2 Mouse monoclonal 1:1000 sc-514302 
Anti-p-RSK1 Rabbit monoclonal 1:1000 Millipore: 04-419 
Anti-RSK1 Rabbit monoclonal 1:1000 sc-231 
Anti-p-ELK1 Rabbit monoclonal 1:1000 Cell signalling: 9181 
Anti-ELK1 Rabbit monoclonal 1:1000 Cell signalling: 9182 
Anti-p-MEK Rabbit monoclonal 1:1000 Millipore: 07-852 
Anti-MEK Rabbit monoclonal 1:1000 Cell signalling: 8727S 
Anti-p-RAF Rabbit monoclonal 1:1000 sc-7267 




6.8, 20% Glycerol, 0.1% Bromophenol blue). Employing SDS-free running buffer, samples were 
run in an 8% acrylamide gel without SDS at 80 V continuous voltage for one hour and a half. 
Membrane transfer was performed at 400mA for 80 minutes.  The stages that follow are the same 
as those outlined in the Immunoblotting methodology.  
4.7 Measurement of proliferation and survival rates 
A549 cells were plated at 30,000 cells/well density in 24-well plates, washing and adding new 
drug every 24 hours. In order to quantify cell number, cells were washed with PBS and detached 
from the plates with Trypsin/EDTA. Cells were counted in a Neubauer Chamber at different times 
(24, 48, 72 and 96 hours). For these cells were mixed with Tripan Blue at a 1:1 ratio to differentiate 
dead cells from the others. The data was imported into GraphPad Prism, where it was normalized 
to a percentage of the control. All samples were triplicated. 
4.8 IC50 calculation 
 
Figure 4. Scheme of the general steps followed for the determination of IC50 using a viability 
assay in A549 cells.  
A549 cells were plated at 3,000 cell/well density in 96-well plate. Cells were treated with a 
gradient of drug concentration, except the control wells. All samples were triplicated.  After 24 
hours, 10µL of Presto Blue Viability Reagent (Invitrogen) was added to each well. Presto Blue 
Cell Viability Reagent is a prepared resazurin-based solution that acts as a cell health indicator 
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by quantifying viability using the reducing power of live cells. When resazurin enters live cells, 
it is converted to resorufin, a red molecule with a strong fluorescence. After1-2 hours of 
incubation at 37ºC, the absorbance was measured at 540nm and 620nm using a 
spectrophotometer. The 540nm/620nm index was calculated in Excel. The values were exported 
to GraphPad Prism and were normalized to a percentage of the control. The IC50 was calculated 
and the graphical representation of the experiment was performed using the same software 
4.9 Preparation of cells for confocal fluorescence microscopy 
For migration assays, cells were previously marked with Cell Tracker Green (Invitrogen), a 
fluorescent dye well suited for monitoring cell movement or location. Starved cells were 
incubated with 10 µL of a 10mM solution of the dye for one hour. Then cells were washed and 
10% FBS DMEM was added for 30 minutes. After that, cells were trypsinized and counted. After 
the assay, fixed cells were treated with a solution of Hoechst 33258 (blue) to mark cell nucleus, 
and phalloidin (red) to mark cell cytoskeleton in a 1:100 PBS solution. 
4.10 Cell migration analysis  
The assay was performed using Transwells, which contained a polycarbonate membrane with an 
8μm pore. The cells could migrate through the pore to the other side of the membrane. A549 cells 
were plated at 50,000 cells/well density and 150 µL of serum-free DMEM was added. 500 µL of 
DMEM containing 5% FBS was added to the down-compartment. After 24 hours, cells were 
washed in PBS, and then cells in the upper side of the transwell membrane where removed. The 
remaining cells were fixed using 4% paraformaldehyde (PFA). Another wash was performed 
before staining the cells with methyl violet. After ten minutes, the wells where washed several 
times in PBS. Lastly, the methyl violet was removed from the cells using an acetic acid solution, 
which was used for quantification. The absorbance of every condition was measured using a 
spectrophotometer (540nm). To evaluate the results and statistical significance of experimental 
groups, Graph Pad Prism software was used to normalize the results and to perform a Student T-
test for each condition. The absorbance of each sample (two per condition) was measured twice. 
4.11 Cell invasion analysis 
Previously, the transwell membranes were covered with 50μL of matrigel resuspended on serum-
free DMEM (1:20). A549 cells were plated at 50,000 cells/well density and 150 µL of serum-free 
DMEM was added. 500 µL of DMEM containing 5% FBS was added to the down-compartment. 
After 48 hours, cells were washed in PBS, and then cells in the upper side of the transwell 




4.12 Preparing tumour cells for grafting 
The cells were removed from their culture dishes using trypsin/EDTA after being washed twice 
in PBS 1X to eliminate any remaining medium. Neubauer Chamber was used to count the cells, 
which were then resuspended at 40 million cells/ml (106 cells/0,025L) in serum-free DMEM. 
4.13 Chicken embryo xenografting 
Freshly fertilized chicken eggs (Gibert Farm Tarragona, Spain) were incubated for 10 days at 37 
degrees Celsius and 60% humidity, rotating every 30 minutes. The eggs were put horizontally on 
an eggcup on day 10. The top of the egg was disinfected using povidone-iodine. Then, the egg 
was pierced at the air sack side using a 30-gauge syringe needle After that, a little perforation of 
the eggshell was made using Dremel rotary tool kit. It was important that this hole penetrated the 
eggshell but not the CAM. Afterwards, a third extremely small hole in the eggshell membrane 
was made with a 20-gauge syringe needle with a little hook on the end. To lower the CAM and 
separate it from the top, liquid was vacuumed at the air sack hole using an automatic pipette aid 
fitted with a piece of Tygon tubing. Then, eggshell fragments were removed to make a small 
window at the top to expose the underlying CAM. A micropipette was used to place 25 µL of cell 
suspension over the exposed CAM. To allow the cells to settle, the window in the egg was 
securely covered with laboratory tape and the eggs were left with the embryos standing upwards 
for a few minutes. The eggs were then placed on an egg rack in a stationary incubator at 37 degrees 
Celsius and 60% relative humidity. For a macroscopic tumour to appear, cells were allowed to 
develop for 2 days. When the tumour was visible, they were treated with 25 µL of a 1:100 drug 
or vehicle dilution in PBS1X. The embryos were treated again after 24 hours. 
 
 
Figure 5. Experimental planning scheme of chick embryo xenografting. At day 1 of the 





Figure 6. Overview of the main stages of the preparation of eggs for tumour cell xenografting. 
(Crespo & Casar, 2016). 
 
4.13 Harvesting tumours and chick embryo tissues 
At the fifth day, the primary tumour is detached from the CAM and weighed. They were 
maintained in 500 µL of 4% PFA at 4ºC. After one day, they were stored at -20ºC. The chick 
embryo was separated from the eggshell using a radial cut, and the embryo was deposited into a 
clean weight basket. The head was cut from the rest of the body through the neck. The embryo 
was dissected with sterile equipment. The CAM, the brain, the liver, and the lungs were collected 
in pieces and placed in microcentrifuge tubes. After extraction, organs were stored at -20ºC. 
4.14 Genomic DNA isolation 
Samples were added 600 µL of Cell Lysis Buffer (Qiagen) with 0.03% of proteinase K. For 
chicken embryo organs, samples were disaggregated using Polytron. The samples were then 
incubated overnight at 60ºC. The next day, 200 µL of protein precipitation solution was mixed 
with the samples. After a 5-minute centrifugation at 13000 rpm, supernatant was rescued, and 
isopropanol was added at 1:1 ratio. A few minutes after, another 5-minute centrifugation at 13000 
rpm was performed. Supernatant was discarded and the genomic DNA pellet was washed three 
times using 70% ethanol. After the final centrifugation, the pellet was completely dried. Finally, 
it was resuspended in 200 µL of hydration solution. The genomic DNA was quantified using 
Nanodrop (Thermo Scientific). 1 µL of DNA was used for the quantification. 
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4.15 RT-qPCR analysis 
The PCR was carried out in a total reaction volume of 20 µL, comprising 19 µL of SYBR Select 
Master Mix (Applied Biosystems) with ultrapure water (1:1), 20 ng of genomic DNA, and 0.05 
µL of each ALU primer (sense: 5'-ACGCCTGTAATCCCAGGACTT-3'; antisense: 5'-
TCGCCCAGGCTGGCTGGGTGCA-3'). A standard curve was created utilizing a dilution of 
human DNA from the A549 cells (102, 103, 104) as a positive control and water as a negative 
control. All samples had duplicates. The PCR was performed at 95°C for 2 minutes, followed by 
40 cycles of 30 seconds at 95°C, 30 seconds at 63°C, and 30 seconds at 72°C. Ct values were 
extrapolated to the standard curve to determine the number of tumour cells present in brain, CAM, 
lung, and liver samples. A Student T-test was performed to examine the results and statistical 






5.1 DEL-22379 inhibits ERK dimerization without affecting its phosphorylation in A549 cells  
First, to make sure DEL-23379 stock maintained its 
properties, a small experiment was performed using 
human embryonic kidney HEK 293T cells (Figure 7). 
To check it, native electrophoresis was performed using 
the total lysates of the cells, previously treated with 
DEL-22379 for one hour and stimulated with EGF for 5 
minutes. The inhibitor could avoid the formation of 
dimers as observed in previous studies (Herrero et al., 
2015). The next experiment (Figure 8) consisted in 
finding out if DEL-22379 could prevent ERK 
dimerization in lung adenocarcinoma human A549 cells. 







Figure 8. ERK dimerization analysis in A549 cells using native gel electrophoresis. The dimer 
runs faster in the gel because it has a greater negative charge and dipole moment, due to the 
embedding of charged residues during dimerization. DMSO was used as a vehicle for the drugs. 
U0 (U0126) and PD (PD-0325901) were used at a final concentration of 10 µM. DEL-22379 was 
used at the indicated µM final concentrations. Membrane was incubated with anti-ERK2 primary 
antibody. 
EGF treatment of A549 cells stimulated the propagation of the signal and induced ERK 
dimerization. DMSO, used as a drug solvent, had no effect in the formation of dimers. U0126 and 
PD-0325901 at 10 µM completely prevent ERK dimerization due to their activity upstream of 
ERK. Low concentrations of DEL-22379 did not have a significant effect, but 10 µM 
concentration or higher could effectively inhibit ERK dimerization, although the membrane was 
Figure 7. DEL-22379 prevents 
ERK dimerization in HEK 293T 
cells. A cell plate was left with no 
EGF stimulation (ST). DEL-22379 
(DEL) concentration used was 10 
µM. Membrane was incubated with 




not clear enough. Thus, the same experiment was carried using DEL-22379 concentrations 
between 10 and 20 µM, to further investigate its inhibiting capabilities in that range (Figure 9). 
Figure 9. ERK dimerization inhibition 
by DEL-22379 in A549 cells. Cells were 
treated with various concentrations of 
DEL-22379 to confirm its inhibitory 
properties. Membrane was incubated 
with anti-ERK2 primary antibody. 
 
As it has been previously explained, DEL-22379 can prevent ERK dimerization without changing 
its phosphorylation state. To check if this was also true for A549 cells, a SDS-PAGE was 
performed with the same lysates (Figure 10). First, the membranes were incubated with a p-ERK 
primary antibody to examine the phosphorylation state of ERK in the cells. Then, the total levels 
of ERK1/2 were inspected to verify that a change of intensity of the signal correspond to a lower 
phosphorylation rate and not to a variation in total protein concentration.  
 
Figure 10. Visualization of ERK phosphorylation (Tyr 204) levels in response to DEL-22379, 
U0126 and PD-0325901. ERK phosphorylation was not affected by the treatment with DEL-
22379 at different concentrations, while it was lower in cells treated with U0126 and PD-
0325901. The ERK1/2 total amount was the same for all the samples. 
The disruption of the formation of ERK dimers implies a greater proportion of ERK monomers 
in the cell. The activation of the cytoplasmic substrates of ERK requires of ERK dimers, while 
the nuclear substrates are activated by monomers. Therefore, the inhibition of ERK dimerization 
would theoretically lower the levels of phosphorylated cytoplasmic substrates while increasing 
the phosphorylation of nuclear ones because there is more ERK monomer available, as it has been 
described by Herrero et al. Thus, the phosphorylation state of these substrates was examined in 
A549 cells treated with DEL-22379 (Figure 11). The Ribosomal s6 kinase alpha-1 (RSK-1) was 
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RSK-1 and ELK-1 phosphorylation levels were much lower in DEL-22379-treated cells when 
compared to non-treated cells. While p-RSK1 levels correlate with previous results in colorectal 
and melanoma cells, p-ELK1 levels are reduced instead of increasing. In order to try to explain 
this decrease in p-ELK1, the activation of other components of the pathway was checked. MEK 
and RAF activation was inspected looking at their respective phosphorylation state (Figure 12). 
 
Figure 12. MEK and RAF 
phosphorylation levels are lower 
in cells treated with high 
concentrations of DEL- 22379. 
Band intensity of MEK was the 
same for all samples. The 
measurement of total RAF levels 
was not possible, so total protein 
concentration was compared using 
alpha-tubulin levels.  
 
Phosphorylated MEK showed a slightly lower general levels in DEL-22379-treated cells, showing 
a more significant decrease at 17,5 and 20 µL. p-RAF also exhibited a reduction of activation 
state at high DEL-22379 concentrations. 
Figure 11. Phosphorylation 
state variation of ERK 
substrates in response to 
DEL-22379 in A549 cells. 
Phosphorylation levels of 
RSK-1 and ELK-1 were 
considerably lower in DEL 
treated cells. Total amount of 
RSK-1 and ELK-1 was the 
same for every sample.  
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5.2 DEL-22379 IC50 calculation in A549 cells 
After the molecular characterization of DEL-22379 inhibition in A549 cells, its biological effects 
on cultured tumour cells were investigated. The cytostatic effects of DEL-22379, U0126 and PD-
0325901 were analysed by calculating the half maximal inhibitory concentration (IC50) of each 
drug in A549 cells, using a viability assay (Figure 13). The cells were cultured in a 96-well plate 
at 3,000 cells per well density. Then, they were treated with a specific concentration of the 
inhibitor in each well, constituting a gradient. After 24 hours, the viability of the cells was 
measured using Presto Blue Viability Reagent and spectrophotometry, as described in Materials 
and Methods.   
 
Figure 13. Results of the IC50 calculation. Graphical representation of the percentage of cell 
viability normalized to the control(y-axis) vs the logarithmic value of inhibitor concentration (x-
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axis) for U0126 (A), DEL-22379 (B) and PD-0325901(C). The graphics were constructed using 
the values in the adjacent table to each chart. 
A549 cells showed a high sensitivity to the MEK inhibitor U0126 (IC50=0.2314 µM) and a 
moderate response to DEL-22379 (IC50=9.368 µM). On the other hand, PD-0325901 did not 
exhibit a good performance in the experiment, minimally reducing cell viability, except for high 
concentrations.  
Considering these results, and examining previous ERK dimerization analysis and 
immunoblotting, the DEL-22379 concentration selected for following experiments was 10 µM.  
5.3 DEL-22379 effectively diminishes cell survival in lung adenocarcinoma cells 
 
Figure 14. A549 cell survival timelapse for different MAPK inhibitor treatments. The charts 
represent the survival rate of A549 cells (normalized to the number of initial cells) (y-axis) for 
different days (x-axis). All drugs were used at 10 µM final concentration. Five different drug 
conditions were set, which can be identified by the title of the graphic. The last graphic (F) 
summarizes all the results for comparation. 
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The aim of the next experiment (Figure 14) was to observe the effects of each inhibitor in cell 
survival and proliferation. Therefore, cells were cultured in a 24-well plate at 30.000 cells/well 
density and treated with a final drug concentration of 10 µM. Five different conditions were set: 
DEL-22379, U0126, PD-0325901 and the combination of DEL-22379 with the two MEK 
inhibitors. Every 24 hours, alive cells were counted for each drug condition. A cell survival curve 
was made with the results. 
Surprisingly, DEL-22379 showed a significantly higher survival suppression than U0126, 
although the last one had a lower IC50, as shown in the preceding experiment. PD-0325901 could 
prevent cell proliferation, but its effects in cell survival were of little importance, as well as its 
outcome in combination with DEL-22379. However, the mixture of U016 and DEL-22379 
treatment in A549 cells resulted in a great decrease of cell proliferation and survival, showing a 
synergistic tendency.  
5.4 A549 cells migration is reduced by the ERK dimerization inhibitor DEL-22379 
Next, the migration and invasion capabilities of A549 
cells were tested in a Transwell assay. In these 
experiments, cells were placed in the top of the porous 
membrane of a small well (Figure 15), which was 
contained inside a bigger well. Serum-starved cells were 
able to migrate through the pores in response to a 
stimulus (5% FBS), which was located into the big well. 
For the invasion assay, a layer of Matrigel was set over 
the membrane, simulating the extracellular matrix.  
To get a more precise measurement of cell migration than 
with other traditional methods, quantification of the cells 
using confocal fluorescence microscopy was tried. Cells 
were prepared for microscopy as explained in the technical 
procedure section. Several pictures of each well were taken 
(an example of this images can be seen in Figure 16). 
However, quantification of the pictures was not possible 
due to the curvature of the porous membrane. Because of 
this curvature, the Z dimension from the microscopy pictures did not correspond with the real 
position of the cells in the membrane, what made software quantification very problematic. 
Hence, the fluorescence images were used for illustration purposes, and other quantification 
technique was performed. 
Figure 15. Representation of cell 
migration (A) and invasion (B) 
assays. Cells were cultured in the 
upper layer of the membrane. A549 
cells could migrate through the 0,8 




Figure 16. Visualization of cell migration using confocal fluorescence microscopy. Two 
conditions are compared in this figure: control cells (A) and DEL-22379 (B). Cells were marked 
with green, blue, and red fluorophores. For both conditions, a schematic illustration of the wells 
after the cell migration is represented. Next, and orthogonal view of the two layers of the porous 
membrane can be seen. Finally, the last images were taken at the lower layer of the membrane. 
Control cells (A) could easily migrate through the membrane to the lower layer in response to the 
stimulus, and they could proliferate too. In contrast, DEL-22379 treated cells (B) migration was 
reduced, so cells remained in the upper layer of the membrane. Few treated cells could migrate 
to the lower layer.  
 
Figure 17.  Migratory and invasive response of A549 cells to MAPK inhibitor treatment. The 
graphics show the relative (compared to control) absorbance of the acetic acid and methyl violet 
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solution (x-axis) for all the experimental conditions (y-axis). The bar chart represents the average 
value, and an analysis of variance was performed using a student t-test.  * = P-value<0.05. ** = 
P-value<0.01. ns = non-significant. A) Transwell migration assay. B) Transwell invasion assay. 
All drugs were used at 10 µM final concentration. 
An alternative quantification method was performed. Thus, A549 cells in the upper layer were 
removed, and cells in the lower layer were stained using methyl violet. Then, the cells were 
washed, and the dye was dissolved in an acetic acid solution. Therefore, the more cells migrated 
to the lower layer of the porous membrane, the more methyl violet was dissolved in this solution. 
Each sample (two per condition) absorbance was measured in duplicates. This method was used 
for both migration and invasion assays (Figure 17). 
A549 cells showed a significant decrease in their migratory function when treated with DEL-
22379 and U0126, while PD-0325901 did not exhibit good outcome. The combination of ERK 
and MEK inhibitor resulted to be the most optimal condition in order to inhibit A549 migration. 
On the other hand, DEL-22379 was not significantly effective to suppress the invasive behaviour 
of A549 cells, as well as PD-032591. Only U0126 showed significant results in the invasion assay.  
5.5 DEL-22379 reduces tumour growth in the chick embryo model 
Finally, to determine the behaviour of lung 
adenocarcinoma cells in vivo, 1.000.000 cells were 
placed in the chorioallantoic membrane of chick 
embryos at day 10 of their development, as described in 
Materials and Methods. Four conditions were established 
based on former results: control, DEL-22379, U0126 and 
U0126+DEL-22379. At day 15, tumours were harvested. 
A significant reduction of tumour weight in the three 
inhibitor conditions compared with control tumours 
could be observed (Figure 18).   
A RT-qPCR was performed with genomic DNA samples 
from brain, CAM, lung, and liver of the chick embryos. 
Human Alu sequence were amplified from the chick 
embryo samples and from DNA samples from a known 
number of A549 cells. However, the values of the chick 
embryo samples were too low, indicating almost no 
















































Figure 18. Graphical 
representation of tumour weight. 
Tumours were harvested and 
weighted. A Student t-test was 
performed to compare treated 
tumours with controls. * = P-




ERK dimerization has been established as a good target against tumour progression and 
oncogenesis (Casar et al., 2008; Herrero et al., 2015; Tomasovic et al., 2020). For this reason, the 
discovery of new compounds capable of preventing the formation of ERK dimers has become a 
viable approach to develop new therapeutic strategies. Herrero et al. demonstrated that the ERK 
inhibitor DEL-22379 had antineoplastic properties in colorectal cancer and melanoma. In 
addition, this study has explored DEL-22379 therapeutic potential in lung adenocarcinoma with 
interesting results. 
 DEL-22379 could inhibit ERK dimerization in A549 lung adenocarcinoma cells without 
changing ERK phosphorylation. This functional specificity of the inhibitor, which just partially 
suppresses ERK activity, could mean less side effects when comparing it with other ERK 
inhibitors. The preservation of ERK phosphorylation would allow usual nuclear activity in normal 
cells, while the inhibition of dimerization would prevent the oncogenic effects of cytoplasmic 
substrates in tumour cells. In fact, DEL-22379 exhibited a mild toxicity in several mice 
experiments (Herrero et al., 2015). In concordance with previous results, the activation of the 
cytoplasmic ERK substrate RSK-1 was reduced with DEL-22379 treatment. However, the 
activation of the nuclear substrate ELK-1 also diminished. There are several hypotheses 
explaining this phenomenon that could be investigated in the future. 
First, Tomasovic et al. recently described a new ERK dimerization inhibitor called EDI, which 
also showed antitumour effects in human colorectal and lung cancer (Tomasovic et al., 2020). As 
DEL-22379, the treatment with EDI did not affect phosphorylation of the TEY motif (Tyr 204) 
but reduced the phosphorylation of the threonine 188. They identified the phosphorylation of this 
residue as necessary for nuclear substrate activation. The inhibition of ERK dimerization 
prevented the autophosphorylation of the threonine 188 of ERK, which also could be happening 
in A549 cells. Thus, it would be interesting to analyse the phosphorylation residue in colorectal, 
melanoma and lung cancer cells to find out the role of this residue in the ERK signalling of cancer 
cells.  
Furthermore, it was noticed that RAF and MEK activation levels were also reduced in DEL-
22379-treated cells. This could happen because of various mechanism, like crosstalk with other 
signalling pathways, the alteration of ERK feedback loops or off-target effects of DEL-22379. 
Although RAF and MEK activation was lower, phosphorylation of the ERK TEY motif did not 
change with DEL-22379 treatment, maybe because RAS mutant cells have a continuous activation 
of the pathway, and this does not considerably affect ERK activation. Nonetheless, this could be 
somehow affecting nuclear substrate phosphorylation. The generation of ERK mutant cells unable 
to bind to DEL-22379 could be useful to discard off-target effects of the drug in RAF, MEK, and 
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other components of the cascade. There could also be off-target effects in other signalling 
pathway.  If these theoretical mutant cells are treated with DEL-22379 and the same effect in p-
ELK1 is observed, it would indicate non-specific interactions.  
In vitro, DEL-22379 supressed cancer cell proliferation, survival, and migration. These effects 
were comparable with the ones induced by the MEK inhibitor U0126, although A549 showed 
more sensitivity to U0126 in the A549 cell viability and migration assays. Nevertheless, DEL-
22379 presented better capabilities to inhibit cell survival, what may happen because of DEL-
22379’s ability of inducing a significant apoptotic response in K-RAS mutant cancer cells (Herrero 
et al., 2015). Moreover, the combination of both DEL-22379 and U0126 inhibitors was the 
optimal condition against tumour cells. ERK and MEK inhibitor treatment has been suggested as 
an effective therapeutic combination (Liu et al., 2018). However, U0126 had not performed well 
outside the laboratories (Frémin & Meloche, 2010). It would be interesting to test the synergistic 
behaviour of DEL-22379 with other more clinically successful MEK inhibitors. 
Contrarily, PD-0325901 showed almost no effect in any of the experiments. These results 
corroborate previous findings obtained in other K-RAS mutant cancer cells, where PD-0325901 
failed to produce a sustained suppression of MAPK pathway signalling (Lito et al., 2014). Their 
findings imply that drugs that not only decrease the catalytic activity of MEK, but also diminish 
its reactivation by C-RAF, may be more effective in inhibiting ERK signalling in these cancers. 
Moreover, PD-0325901 did not performed well in clinical trials with NSCLC patients (Haura 
et al., 2010).  Therefore, these kind of properties of MEK inhibitors should be considered when 
choosing a DEL-22379 partner in future experiments or clinical trials for K-RAS mutant cancers.  
DEL-22379 did not perform well in the invasion assay. The number of cells that could reach the 
lower layer was smaller than in the control, but still not significant. The relative effectiveness of 
U0126 was also decreased in this experiment. Instead of assuming a lower efficacy of this 
inhibitors to supress tumour cell invasion, a problem with the quantification technique is more 
likely to explain these results. The crystal violet method showed enough sensitivity in the 
migration assay, where cells migrate much more easily than in the invasion conditions. Because 
of the Matrigel, there is a smaller number of total cells that can invade and migrate to the lower 
layer of the membrane, what makes quantification more inaccurate. In fact, the absolute 
absorbance values were approximately ten times lower than in the migration assay. This could 
explain the lack of significance of the results. Another more sensitive method of quantification 
should be used for future invasion assays. 
The tumour growth of lung adenocarcinoma in chick embryo model was reduced by DEL-22379 
and U0126, and the combination of both resulted in a greater reduction. Unfortunately, none of 
the tumours achieved to metastasise to any of the chick embryo’s organs analysed. This could be 
33 
 
resolved by allowing tumour growth and dissemination up to day 17 of development. However, 
the experiment was conducted with an initial inoculation of one million cancer cells per embryo. 
This, plus the high growth capacity of this A549 cells, would have likely killed the chick embryo 
before the day 17. In fact, many of the embryos died during the week of tumour formation (day 
10 to day 15). Moreover, in our laboratory, we have previously demonstrated aggressiveness 
inversely correlates with tumour size in some tumours (García-Ibáñez et al., 2020). Hence, the 
experiment could be repeated using a smaller number of cells, which could provide enough time 























From this work, the following conclusions can be made: 
• DEL-22379 can inhibit the formation of ERK dimers in A549 cells without altering the 
TEY motif phosphorylation. 
• Both activation of nuclear and cytoplasmic ERK substrates are lowered by DEL-22379 
in lung adenocarcinoma cells. 
• DEL-22379 reduces proliferation, survival, and migration of lung adenocarcinoma cells. 
This reduction is comparable with U0126 inhibition, another MAPK pathway inhibitor.  
• DEL-22379 diminishes A549 tumour growth in the chick embryo model. 
• DEL-22379 shows a synergistic tendency with MEK inhibitors like U0126 in A549 cells, 
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